HealthEquity (NASDAQ:HQY) PT Raised to $110.00

HealthEquity (NASDAQ:HQY) had its price objective boosted by investment analysts at Wells Fargo & Company from $107.00 to $110.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 29.81% from the stock’s current price.

Several other brokerages have also weighed in on HQY. Bank of America increased their price objective on shares of HealthEquity from $97.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. KeyCorp raised their price target on shares of HealthEquity from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. JMP Securities raised their price target on shares of HealthEquity from $101.00 to $105.00 and gave the company a “market outperform” rating in a report on Tuesday, June 4th. Raymond James raised their price target on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Finally, BTIG Research raised their price target on shares of HealthEquity from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.

HealthEquity Trading Up 0.4 %

Shares of HQY stock opened at $84.74 on Thursday. The firm has a market cap of $7.37 billion, a P/E ratio of 92.11, a PEG ratio of 1.43 and a beta of 0.55. HealthEquity has a 1-year low of $59.02 and a 1-year high of $87.72. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.39 and a quick ratio of 4.39. The firm’s 50-day simple moving average is $80.56 and its 200-day simple moving average is $77.39.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.08. The business had revenue of $262.39 million for the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a net margin of 7.71% and a return on equity of 7.77%. As a group, equities analysts forecast that HealthEquity will post 2.12 EPS for the current year.

Insider Activity at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 400 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $85.00, for a total value of $34,000.00. Following the sale, the insider now directly owns 90,515 shares in the company, valued at $7,693,775. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Jon Kessler sold 33,765 shares of HealthEquity stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares of the company’s stock, valued at approximately $10,106,739.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Stephen Neeleman sold 400 shares of HealthEquity stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total value of $34,000.00. Following the completion of the transaction, the insider now directly owns 90,515 shares in the company, valued at approximately $7,693,775. The disclosure for this sale can be found here. Insiders have sold a total of 68,745 shares of company stock worth $5,482,530 over the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On HealthEquity

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in HealthEquity by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after acquiring an additional 149,133 shares in the last quarter. Wasatch Advisors LP grew its stake in shares of HealthEquity by 8.3% in the 1st quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock valued at $604,803,000 after buying an additional 569,249 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in shares of HealthEquity by 3,001.0% in the 1st quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock valued at $307,097,000 after buying an additional 3,640,748 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of HealthEquity by 6.9% in the 4th quarter. Clearbridge Investments LLC now owns 2,357,572 shares of the company’s stock valued at $156,307,000 after buying an additional 152,897 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of HealthEquity by 58.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company’s stock valued at $119,831,000 after buying an additional 664,979 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.